Oxford Nanopore Technologies plc (LON:ONT) has announced its Full Year Trading Update and Notice of Results
Strong 2025 performance; full year revenue growth slightly ahead of guidance
· The Group expects to report revenue of approximately £223 – £224 million (FY24: £183.2 million), representing growth of approximately 22% on a reported basis and 24% at constant currency, slightly ahead of the Group’s guidance range of 20-23% constant currency growth.
· Continued progress on path to profitability.
Broad-based growth across all geographies, customer end markets and product categories
· Continued commercial momentum with revenue growth increasing by more than 20% constant currency across each region (EMEAI, APAC and AMR).
· Across customer end markets, Clinical revenue grew by approximately 60% on a reported basis, BioPharma by approximately 30% and Applied Industrial by approximately 27%. Research revenue grew by approximately 15% during the period despite end-market funding pressures.1
· Growth was delivered across all product types, led by the PromethION range, which grew by more than 40% year-on-year on a reported basis.
Business remains well capitalised to deliver on its goals
· Oxford Nanopore ended the year with approximately £302 million in cash, cash equivalents and other liquid investments as at 31 December 2025 (FY24: £403.8 million), ahead of consensus expectations helped by improving working capital, providing continued balance sheet strength to support execution of the Group’s strategy.
Notice of Results
· Oxford Nanopore will announce its preliminary annual results for the twelve months ended 31 December 2025 on Monday 2 March 2026.
· Management will host a virtual presentation on the same day at 9:30am GMT / 4:30am EST, followed by a Q&A session accessible via webcast and conference call.
Notes:
(1) The FY24 customer end market comparatives have been re-presented following a refinement of the data categorisation during the year. There has been no change to the overall FY24 revenue number however there has been a reclassification of £1.9 million from Applied Industrial and £1.0 million from BioPharma to the Research (£1.6 million) and Clinical (£1.3 million) markets.
– Constant currency (CC) applies the same rate to the FY25 and FY24 non-GBP results based on FY24 rates.
– All percentages compare to the equivalent 2024 period.
– APAC: Asia Pacific, AMR: The Americas, EMEAI: Europe, the Middle East, Africa and India
